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Letters to the Editor
Platelet Function Testing and Prediction of Bleeding
in Patients Exposed to Clopidogrel Undergoing
Coronary Artery Surgery
Reed GW et al. Clin Cardiol. 2015;38:92–98.
We read with great interest the recently published study by
Reed et al.1 The authors conducted a proof-of-principle,
prospective, observational pilot study of 39 clopidogrel-
treated patients scheduled for on-pump coronary artery
surgery (CAS).1 Briefly, the authors found that the
VerifyNow P2Y12 assay (Accumetrics, San Diego, CA)
can predict bleeding within the first 24 hours after CAS.1
This pilot study certainly adds to the current knowledge;
however, some methodological considerations should be
addressed.
It is important to note that 37 (95%) patients were exposed
to aspirin doses of 81 to 325 mg for ≥7 days prior to
enrollement.1 Of those, 31 (80%) patients were exposed
to aspirin doses ≥324 mg in close proximity (within 24
hours) to surgery.1 Considering preoperative antiplatelet
therapy management, in particular aspirin dosage and
discontinuation management, we may assume that the
lack of aspirin-specific platelet function testing was a
major drawback of the study.1 The VerifyNow system
provides 2 different assays, (1) VerifyNow P2Y12 and
(2) VerifyNow aspirin. VerifyNow aspirin incorporates
the agonist arachidonic acid to activate platelets and has
been shown to reliably detect aspirin effect.2 Recently,
we have conducted a prospective observational study
with the aim to assess bleeding risk using a point-
of-care impedance aggregometer in patients undergoing
CAS.3 Patients transfused with packed red blood cells
had significantly lower aspirin-sensitive platelet function
test values,3 and those values significantly correlated to
the amount of 24-hour chest tube output.3 In our study,
patients were preoperatively exposed to a daily aspirin dose
of 100 mg.3 Thus, we assume that prediction of bleeding
using aspirin-sensitive platelet function testing could be
even more accurate in a group of patients exposed to
more aggressive preoperative aspirin dosage regimens.
This assumption may be further corroborated by the
fact that, when coadministered, aspirin and clopidogrel
achieve greater inhibitory effects on platelet aggregation
than either agent alone.4 The role of aspirin should not
be underestimated. By disregarding the variability in the
individual responsiveness to aspirin, as well as the possibility
that some patients can actually have a profound platelet
inhibitory effect on higher aspirin doses, the authors have
negated the possible independent contribution of aspirin
response as a confounding variable in their pilot study.1
To the best of our knowledge, 2 other studies previously
addressed the prediction of bleeding complications using
the same VerifyNow device in CAS patients.5,6 Of those
studies, one was retrospective analysis,5 whereas another
study was conducted in a prospective observational fashion.6
Still, small cohorts in studies may not be overcome with
pooling of the evidence due to heterogeneity in both study
designs and definitions of excessive bleeding. Findings are
further elusive due to the separate prediction of bleeding
amount and transfusion requirements, which is reasonably
expected to be inversely related. Apparently, we need the
composite outcome consisting of both bleeding amount
and transfusion requirements.5 Standardization of outcomes
is very important for further pooling of the evidence,
and to date, Dyke et al7 provide the most comprehensive
and reliable grading of bleeding outcomes that should be
consistently used and validated through further research.
Finally, our working group would underline some
important considerations for studies evaluating the role of
point-of-care platelet function test devices in CAS patients.
First, preoperative platelet function testing may be useful
in terms of preoperative bleeding risk stratification that
would direct preoperative antiplatelet drug management
as well as timing of surgery. Drug-specific platelet
function tests should inextricably evaluate platelet inhibitory
response to both aspirin and clopidogrel. Furthermore,
point-of-care assessment of platelet function should be
continued to time points during and after cardiopulmonary
bypass, as measurements at these time points may more
accurately detect hemostatic alterations, and thus more
reliably predict bleeding complications by accounting
for accumulative effects of both preoperative antiplatelet
therapy and cardiopulmonary bypass on platelet function.
Second, emerging evidence on early postoperative platelet
hyperactivity suggests the need for postoperative platelet
function assessment aiming to detect patients with high
residual on-treatment platelet reactivity. The comprehensive
approach to patients based on point-of-care platelet function
tests should finally yield a comprehensive algorithm
for personalized management of perioperative antiplatelet
therapy. In such an approach, the risk of excessive
bleeding associated with antiplatelet therapy must always be
weighed against the risk for adverse ischemic events. The
definition of a perioperative ‘‘therapeutic window’’ for the
most commonly administered antiplatelet drugs, as well
as the development of a personalized algorithm based
on point-of-care platelet function assessment, warrants
further investigations that would test the hypotheses
about reduction of both bleeding and adverse ischemic
events in the pre- and postoperative phase associated with
implementation of point-of-care–guided antiplatelet therapy
management.
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We congratulate the authors on their elegant and
timely research. This article certainly sheds light onto
the field and adds to the current knowledge. However,
further efforts to elucidate the role of point-of-care platelet
function analyzers in developing a personalized approach
and optimizing patient outcomes in perioperative setting
are needed. Platelet function is a continuous variable
ranging from weak function to high platelet reactivity,
reflecting in turn a proclivity toward bleeding and ischemic
events, respectively. A personalized approach based on a
predefined therapeutic window is desirable, and requires
further studies standardized in a study design and end
points assessed that would facilitate further pooling of the
evidence. In that regard, multicentric studies, with the
collaboration of centers having the expertise in specific
platelet function test, could be the best way to conduct a
large cohort study. The basic research concept in this field
should be ‘‘from observation to intervention.’’ Observational
studies should first delineate the therapeutic window
(step 1) for aspirin and clopidogrel using a drug-specific
point-of-care platelet function analyzer. The therapeutic
window should be validated (step 2) through interventional
studies assessing both bleeding and adverse ischemic
events.
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